Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| SEELOS THERAPEUTICS, INC.SEEL · Entity 93662 | Director | January 04, 2024 | January 08, 2024 |
| Viking Therapeutics, Inc.VKTX · Entity 4067 | Director · President & CEO | July 28, 2026 | July 30, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
SEELOS THERAPEUTICS, INC.
Report date January 04, 2024 · Filed January 08, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.33 · Expires 2034-01-04 | Direct | 1,666 |
Reported balance
After 2024-01-04 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2024-01-04 · Grant · Acquired 1,666 · Balance 1,666 F1: 1/12th of the shares subject to the option shall vest on February 4, 2024, and 1/12th of the shares subject to the option shall vest monthly thereafter. |
Filing footnotes · ownership attribution and instrument terms
F1: 1/12th of the shares subject to the option shall vest on February 4, 2024, and 1/12th of the shares subject to the option shall vest monthly thereafter.
Viking Therapeutics, Inc.
Report date July 28, 2026 · Filed July 30, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common Stock, par value $0.00001 per shareSEC Table I · non-derivative | Direct | 2,572,441 |
Ending reported balance
After 2026-07-29 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2026-07-28 · Grant · Acquired 221,667 · Balance 2,720,958 F1: The reported securities were subject to a performance restricted stock unit award that was granted on January 3, 2023, 33.33% of which vested on July 28, 2026 upon the achievement of a non-financial performance goal. Row 2 · 2026-07-29 · Sale · Disposed 148,517 · Balance 2,572,441 F2: These shares were automatically sold on a non-discretionary basis solely to satisfy certain tax withholding obligations in connection with the issuance of shares upon the vesting of certain shares of common stock subject to the performance restricted stock unit award described in Footnote 1. F3: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $32.82 to $33.77, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in the this footnote. |
Filing footnotes · ownership attribution and instrument terms
F1: The reported securities were subject to a performance restricted stock unit award that was granted on January 3, 2023, 33.33% of which vested on July 28, 2026 upon the achievement of a non-financial performance goal.
F2: These shares were automatically sold on a non-discretionary basis solely to satisfy certain tax withholding obligations in connection with the issuance of shares upon the vesting of certain shares of common stock subject to the performance restricted stock unit award described in Footnote 1.
F3: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $32.82 to $33.77, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in the this footnote.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| July 29, 2026 Filed Jul 30, 2026 00:07 UTC | Viking Therapeutics, Inc. VKTX · Entity 4067 | SaleCommon Stock, par value $0.00001 per share | 148,517 | $33.32 | $4,947,888.41 |
DisclosureSEC source: 0001193125-26-324448 · ownership.xml · nonDerivative · entry 2 Lian Brian · CIK 0001614578 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,572,441 F2 · shares: These shares were automatically sold on a non-discretionary basis solely to satisfy certain tax withholding obligations in connection with the issuance of shares upon the vesting of certain shares of common stock subject to the performance restricted stock unit award described in Footnote 1. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $32.82 to $33.77, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in the this footnote. Read SEC document |
| July 28, 2026 Filed Jul 30, 2026 00:07 UTC | Viking Therapeutics, Inc. VKTX · Entity 4067 | GrantCommon Stock, par value $0.00001 per share | 221,667 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-324448 · ownership.xml · nonDerivative · entry 1 Lian Brian · CIK 0001614578 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,720,958 F1 · shares: The reported securities were subject to a performance restricted stock unit award that was granted on January 3, 2023, 33.33% of which vested on July 28, 2026 upon the achievement of a non-financial performance goal. Read SEC document |
| January 05, 2026 Filed Jan 6, 2026 01:28 UTC | Viking Therapeutics, Inc. VKTX · Entity 4067 | SaleCommon Stock, par value $0.00001 per share | 6,400 | $35.07 | $224,423.04 |
DisclosureSEC source: 0001193125-26-003113 · ownership.xml · nonDerivative · entry 6 Lian Brian · CIK 0001614578 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,499,291 F4 · shares: These shares were automatically sold on a non-discretionary basis solely to satisfy certain tax withholding obligations in connection with the issuance of shares upon the vesting of certain shares of common stock subject to certain restricted stock unit awards that vested on January 3, 2026 and the performance restricted stock unit awards described in Footnote 3. F8 · price: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $34.88 to $35.20, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| January 05, 2026 Filed Jan 6, 2026 01:28 UTC | Viking Therapeutics, Inc. VKTX · Entity 4067 | SaleCommon Stock, par value $0.00001 per share | 41,276 | $34.22 | $1,412,398.68 |
DisclosureSEC source: 0001193125-26-003113 · ownership.xml · nonDerivative · entry 5 Lian Brian · CIK 0001614578 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,505,691 F4 · shares: These shares were automatically sold on a non-discretionary basis solely to satisfy certain tax withholding obligations in connection with the issuance of shares upon the vesting of certain shares of common stock subject to certain restricted stock unit awards that vested on January 3, 2026 and the performance restricted stock unit awards described in Footnote 3. F7 · price: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $33.87 to $34.85, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| January 05, 2026 Filed Jan 6, 2026 01:28 UTC | Viking Therapeutics, Inc. VKTX · Entity 4067 | SaleCommon Stock, par value $0.00001 per share | 53,279 | $33.38 | $1,778,266.54 |
DisclosureSEC source: 0001193125-26-003113 · ownership.xml · nonDerivative · entry 4 Lian Brian · CIK 0001614578 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,546,967 F4 · shares: These shares were automatically sold on a non-discretionary basis solely to satisfy certain tax withholding obligations in connection with the issuance of shares upon the vesting of certain shares of common stock subject to certain restricted stock unit awards that vested on January 3, 2026 and the performance restricted stock unit awards described in Footnote 3. F6 · price: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $32.87 to $33.865, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| January 05, 2026 Filed Jan 6, 2026 01:28 UTC | Viking Therapeutics, Inc. VKTX · Entity 4067 | SaleCommon Stock, par value $0.00001 per share | 132,454 | $32.29 | $4,277,032.38 |
DisclosureSEC source: 0001193125-26-003113 · ownership.xml · nonDerivative · entry 3 Lian Brian · CIK 0001614578 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,600,246 F4 · shares: These shares were automatically sold on a non-discretionary basis solely to satisfy certain tax withholding obligations in connection with the issuance of shares upon the vesting of certain shares of common stock subject to certain restricted stock unit awards that vested on January 3, 2026 and the performance restricted stock unit awards described in Footnote 3. F5 · price: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $31.87 to $32.865, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| January 02, 2026 Filed Jan 6, 2026 01:28 UTC | Viking Therapeutics, Inc. VKTX · Entity 4067 | GrantStock Option (Right to Buy) · Derivative | 176,300 | $0.00 Strike: $35.42 | $0.00 |
DisclosureSEC source: 0001193125-26-003113 · ownership.xml · derivative · entry 7 Lian Brian · CIK 0001614578 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 176,300 Underlying: Common Stock · 176,300 shares Expires 2036-01-02 F9 · derivative.exercise_date: 25% of the shares subject to the option will vest on each anniversary of the grant date. Read SEC document |
| January 02, 2026 Filed Jan 6, 2026 01:28 UTC | Viking Therapeutics, Inc. VKTX · Entity 4067 | GrantCommon Stock, par value $0.00001 per share | 224,080 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-003113 · ownership.xml · nonDerivative · entry 2 Lian Brian · CIK 0001614578 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,732,700 F3 · shares: The reported securities were subject to a performance restricted stock unit award that was granted on January 3, 2023, 33.33% of which vested on January 2, 2026. upon the achievement of a non-financial performance goal and a second performance restricted stock unit award that was granted on January 3, 2025, 1.665% of which vested on January 2, 2026, upon the partial achievement of a non-financial performance goal. Read SEC document |
| January 02, 2026 Filed Jan 6, 2026 01:28 UTC | Viking Therapeutics, Inc. VKTX · Entity 4067 | GrantCommon Stock, par value $0.00001 per share | 78,400 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-003113 · ownership.xml · nonDerivative · entry 1 Lian Brian · CIK 0001614578 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,508,620 F1 · shares: Represents a restricted stock unit award ("RSU") of common stock under the Issuer's 2024 Equity Incentive Plan. One-third of the shares subject to the RSU shall vest on each one year anniversary of the grant date of the award. F2 · balance_after: Includes 11,111 shares acquired on May 20, 2024 pursuant to the Issuer's 2014 Employee Stock Purchase Plan. Read SEC document |
| October 28, 2025 Filed Oct 28, 2025 23:48 UTC | Viking Therapeutics, Inc. VKTX · Entity 4067 | SaleCommon Stock, par value $0.00001 per share | 38,989 | $35.01 | $1,364,923.01 |
DisclosureSEC source: 0001193125-25-254299 · ownership.xml · nonDerivative · entry 2 Lian Brian · CIK 0001614578 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,419,109 F2 · shares: These shares were automatically sold on a non-discretionary basis solely to satisfy certain tax withholding obligations in connection with the issuance of shares upon the vesting of certain shares of common stock subject to the performance restricted stock unit award described in Footnote 1. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $34.66 to $35.48, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in the this footnote. Read SEC document |
| October 27, 2025 Filed Oct 28, 2025 23:48 UTC | Viking Therapeutics, Inc. VKTX · Entity 4067 | GrantCommon Stock, par value $0.00001 per share | 70,084 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-25-254299 · ownership.xml · nonDerivative · entry 1 Lian Brian · CIK 0001614578 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,458,098 F1 · shares: The reported securities were subject to a performance restricted stock unit award that was granted on January 3, 2025, 33.33% of which vested on October 27, 2025 upon the achievement of a non-financial performance goal and 15% of which vested also on October 27, 2025 upon the partial achievement of a non-financial performance goal. Read SEC document |
| July 03, 2025 Filed Jul 3, 2025 19:31 UTC | Viking Therapeutics, Inc. VKTX · Entity 4067 | SaleCommon Stock, par value $0.00001 per share | 26,889 | $27.80 | $747,632.51 |
DisclosureSEC source: 0000950170-25-093793 · ownership.xml · nonDerivative · entry 2 Lian Brian · CIK 0001614578 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,388,014 F2 · shares: These shares were automatically sold on a non-discretionary basis solely to satisfy certain tax withholding obligations in connection with the issuance of shares upon the vesting of certain shares of common stock subject to the performance restricted stock unit award described in Footnote 1. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $27.70 to $27.86, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in the this footnote. Read SEC document |
| July 02, 2025 Filed Jul 3, 2025 19:31 UTC | Viking Therapeutics, Inc. VKTX · Entity 4067 | GrantCommon Stock, par value $0.00001 per share | 48,333 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-25-093793 · ownership.xml · nonDerivative · entry 1 Lian Brian · CIK 0001614578 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,414,903 F1 · shares: The reported securities were subject to a performance restricted stock unit award that was granted on January 3, 2025, 33.33% of which vested on July 2, 2025 upon the achievement of a non-financial performance goal. Read SEC document |
| January 06, 2025 Filed Jan 7, 2025 01:16 UTC | Viking Therapeutics, Inc. VKTX · Entity 4067 | SaleCommon Stock, par value $0.00001 per share | 19,000 | $43.32 | $823,021.10 |
DisclosureSEC source: 0000950170-25-002487 · ownership.xml · nonDerivative · entry 4 Lian Brian · CIK 0001614578 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,366,570 F3 · shares: These shares were automatically sold on a non-discretionary basis solely to satisfy certain tax withholding obligations in connection with the issuance of shares upon the vesting of certain shares of common stock subject to certain restricted stock unit awards and certain performance restricted stock unit awards. F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $43.19 to $43.48, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| January 06, 2025 Filed Jan 7, 2025 01:16 UTC | Viking Therapeutics, Inc. VKTX · Entity 4067 | SaleCommon Stock, par value $0.00001 per share | 175,490 | $42.68 | $7,490,580.06 |
DisclosureSEC source: 0000950170-25-002487 · ownership.xml · nonDerivative · entry 3 Lian Brian · CIK 0001614578 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,385,570 F3 · shares: These shares were automatically sold on a non-discretionary basis solely to satisfy certain tax withholding obligations in connection with the issuance of shares upon the vesting of certain shares of common stock subject to certain restricted stock unit awards and certain performance restricted stock unit awards. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $42.19 to $43.18, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| January 03, 2025 Filed Jan 7, 2025 01:16 UTC | Viking Therapeutics, Inc. VKTX · Entity 4067 | GrantStock Option (Right to Buy) · Derivative | 78,300 | $0.00 Strike: $42.89 | $0.00 |
DisclosureSEC source: 0000950170-25-002487 · ownership.xml · derivative · entry 5 Lian Brian · CIK 0001614578 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 78,300 Underlying: Common Stock · 78,300 shares Expires 2035-01-03 F6 · derivative.exercise_date: 25% of the shares subject to the option will vest on each anniversary of the grant date. Read SEC document |
| January 03, 2025 Filed Jan 7, 2025 01:16 UTC | Viking Therapeutics, Inc. VKTX · Entity 4067 | GrantCommon Stock, par value $0.00001 per share | 163,333 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-25-002487 · ownership.xml · nonDerivative · entry 2 Lian Brian · CIK 0001614578 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,561,060 F2 · shares: The reported securities were subject to a performance restricted stock unit award that was granted on January 3, 2024, 33.33% of which vested on January 3, 2025 upon the achievement of a non-financial performance goal. Read SEC document |
| January 03, 2025 Filed Jan 7, 2025 01:16 UTC | Viking Therapeutics, Inc. VKTX · Entity 4067 | GrantCommon Stock, par value $0.00001 per share | 92,800 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-25-002487 · ownership.xml · nonDerivative · entry 1 Lian Brian · CIK 0001614578 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,397,727 F1 · shares: Represents a restricted stock unit award ("RSU") of common stock under the Issuer's 2024 Equity Incentive Plan. One-third of the shares subject to the RSU shall vest on each one year anniversary of the grant date of the award. Read SEC document |
| September 20, 2024 Filed Sep 21, 2024 01:20 UTC | Viking Therapeutics, Inc. VKTX · Entity 4067 | Exercise / conversionStock Option (Right to Buy) · Derivative | 166,130 | $0.00 Strike: $7.77 | $0.00 |
DisclosureSEC source: 0000950170-24-108576 · ownership.xml · derivative · entry 5 Lian Brian · CIK 0001614578 · Director · President & CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 65,000 Underlying: Common Stock · 166,130 shares Expires 2030-01-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule10b5-1 trading plan adopted on May 8, 2024 by the Reporting Person. F5 · derivative.exercise_date: 25% of the shares subject to the option vested on each anniversary of the grant date. Read SEC document |
| September 20, 2024 Filed Sep 21, 2024 01:20 UTC | Viking Therapeutics, Inc. VKTX · Entity 4067 | SaleCommon Stock, par value $0.00001 per share | 200 | $71.99 | $14,397.00 |
DisclosureSEC source: 0000950170-24-108576 · ownership.xml · nonDerivative · entry 4 Lian Brian · CIK 0001614578 · Director · President & CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 2,304,927 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule10b5-1 trading plan adopted on May 8, 2024 by the Reporting Person. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $71.97 to $72.00, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| September 20, 2024 Filed Sep 21, 2024 01:20 UTC | Viking Therapeutics, Inc. VKTX · Entity 4067 | SaleCommon Stock, par value $0.00001 per share | 119,874 | $71.15 | $8,529,047.09 |
DisclosureSEC source: 0000950170-24-108576 · ownership.xml · nonDerivative · entry 3 Lian Brian · CIK 0001614578 · Director · President & CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 2,305,127 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule10b5-1 trading plan adopted on May 8, 2024 by the Reporting Person. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $70.90 to $71.89, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| September 20, 2024 Filed Sep 21, 2024 01:20 UTC | Viking Therapeutics, Inc. VKTX · Entity 4067 | SaleCommon Stock, par value $0.00001 per share | 96,056 | $70.43 | $6,765,108.81 |
DisclosureSEC source: 0000950170-24-108576 · ownership.xml · nonDerivative · entry 2 Lian Brian · CIK 0001614578 · Director · President & CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 2,425,001 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule10b5-1 trading plan adopted on May 8, 2024 by the Reporting Person. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $69.90 to $70.89, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| September 20, 2024 Filed Sep 21, 2024 01:20 UTC | Viking Therapeutics, Inc. VKTX · Entity 4067 | Exercise / conversionCommon Stock, par value $0.00001 per share | 166,130 | $7.77 | $1,290,830.10 |
DisclosureSEC source: 0000950170-24-108576 · ownership.xml · nonDerivative · entry 1 Lian Brian · CIK 0001614578 · Director · President & CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 2,521,057 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule10b5-1 trading plan adopted on May 8, 2024 by the Reporting Person. Read SEC document |
| August 21, 2024 Filed Aug 22, 2024 23:23 UTC | Viking Therapeutics, Inc. VKTX · Entity 4067 | Exercise / conversionStock Option (Right to Buy) · Derivative | 1,000 | $0.00 Strike: $7.77 | $0.00 |
DisclosureSEC source: 0000950170-24-099982 · ownership.xml · derivative · entry 3 Lian Brian · CIK 0001614578 · Director · President & CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 231,130 Underlying: Common Stock · 1,000 shares Expires 2030-01-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule10b5-1 trading plan adopted on May 8, 2024 by the Reporting Person. F2 · derivative.exercise_date: 25% of the shares subject to the option vested on each anniversary of the grant date. Read SEC document |
| August 21, 2024 Filed Aug 22, 2024 23:23 UTC | Viking Therapeutics, Inc. VKTX · Entity 4067 | SaleCommon Stock, par value $0.00001 per share | 1,000 | $69.90 | $69,900.00 |
DisclosureSEC source: 0000950170-24-099982 · ownership.xml · nonDerivative · entry 2 Lian Brian · CIK 0001614578 · Director · President & CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 2,354,927 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule10b5-1 trading plan adopted on May 8, 2024 by the Reporting Person. Read SEC document |
| August 21, 2024 Filed Aug 22, 2024 23:23 UTC | Viking Therapeutics, Inc. VKTX · Entity 4067 | Exercise / conversionCommon Stock, par value $0.00001 per share | 1,000 | $7.77 | $7,770.00 |
DisclosureSEC source: 0000950170-24-099982 · ownership.xml · nonDerivative · entry 1 Lian Brian · CIK 0001614578 · Director · President & CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 2,355,927 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule10b5-1 trading plan adopted on May 8, 2024 by the Reporting Person. Read SEC document |
| August 19, 2024 Filed Aug 20, 2024 00:13 UTC | Viking Therapeutics, Inc. VKTX · Entity 4067 | Exercise / conversionStock Option (Right to Buy) · Derivative | 112,870 | $0.00 Strike: $7.77 | $0.00 |
DisclosureSEC source: 0000950170-24-098803 · ownership.xml · derivative · entry 5 Lian Brian · CIK 0001614578 · Director · President & CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 232,130 Underlying: Common Stock · 112,870 shares Expires 2030-01-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule10b5-1 trading plan adopted on May 8, 2024 by the Reporting Person. F5 · derivative.exercise_date: 25% of the shares subject to the option vested on each anniversary of the grant date. Read SEC document |
| August 19, 2024 Filed Aug 20, 2024 00:13 UTC | Viking Therapeutics, Inc. VKTX · Entity 4067 | SaleCommon Stock, par value $0.00001 per share | 11,296 | $67.12 | $758,194.30 |
DisclosureSEC source: 0000950170-24-098803 · ownership.xml · nonDerivative · entry 4 Lian Brian · CIK 0001614578 · Director · President & CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 2,354,927 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule10b5-1 trading plan adopted on May 8, 2024 by the Reporting Person. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $66.9302 to $67.55, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| August 19, 2024 Filed Aug 20, 2024 00:13 UTC | Viking Therapeutics, Inc. VKTX · Entity 4067 | SaleCommon Stock, par value $0.00001 per share | 31,442 | $66.37 | $2,086,821.26 |
DisclosureSEC source: 0000950170-24-098803 · ownership.xml · nonDerivative · entry 3 Lian Brian · CIK 0001614578 · Director · President & CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 2,366,223 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule10b5-1 trading plan adopted on May 8, 2024 by the Reporting Person. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $65.93 to $66.9091, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| August 19, 2024 Filed Aug 20, 2024 00:13 UTC | Viking Therapeutics, Inc. VKTX · Entity 4067 | SaleCommon Stock, par value $0.00001 per share | 70,132 | $65.33 | $4,581,492.12 |
DisclosureSEC source: 0000950170-24-098803 · ownership.xml · nonDerivative · entry 2 Lian Brian · CIK 0001614578 · Director · President & CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 2,397,665 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule10b5-1 trading plan adopted on May 8, 2024 by the Reporting Person. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $64.90 to $65.8919, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| August 19, 2024 Filed Aug 20, 2024 00:13 UTC | Viking Therapeutics, Inc. VKTX · Entity 4067 | Exercise / conversionCommon Stock, par value $0.00001 per share | 112,870 | $7.77 | $876,999.90 |
DisclosureSEC source: 0000950170-24-098803 · ownership.xml · nonDerivative · entry 1 Lian Brian · CIK 0001614578 · Director · President & CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 2,467,797 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule10b5-1 trading plan adopted on May 8, 2024 by the Reporting Person. Read SEC document |
| July 30, 2024 Filed Jul 31, 2024 20:05 UTC | Viking Therapeutics, Inc. VKTX · Entity 4067 | SaleCommon Stock, par value $0.00001 per share | 30,417 | $58.78 | $1,787,911.26 |
DisclosureSEC source: 0000950170-24-088544 · ownership.xml · nonDerivative · entry 5 Lian Brian · CIK 0001614578 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,354,927 F3 · shares: These shares were automatically sold on a non-discretionary basis soley to satisfy certain tax withholding obligations in connection with the issuance of shares upon the vesting of certain shares of common stock subject to certain performance restricted stock unit awards. F6 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $58.46 to $59.00, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| July 30, 2024 Filed Jul 31, 2024 20:05 UTC | Viking Therapeutics, Inc. VKTX · Entity 4067 | SaleCommon Stock, par value $0.00001 per share | 19,501 | $57.81 | $1,127,352.81 |
DisclosureSEC source: 0000950170-24-088544 · ownership.xml · nonDerivative · entry 4 Lian Brian · CIK 0001614578 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,385,344 F3 · shares: These shares were automatically sold on a non-discretionary basis soley to satisfy certain tax withholding obligations in connection with the issuance of shares upon the vesting of certain shares of common stock subject to certain performance restricted stock unit awards. F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $57.46 to $58.45, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| July 30, 2024 Filed Jul 31, 2024 20:05 UTC | Viking Therapeutics, Inc. VKTX · Entity 4067 | SaleCommon Stock, par value $0.00001 per share | 65,941 | $56.95 | $3,755,339.95 |
DisclosureSEC source: 0000950170-24-088544 · ownership.xml · nonDerivative · entry 3 Lian Brian · CIK 0001614578 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,404,845 F3 · shares: These shares were automatically sold on a non-discretionary basis soley to satisfy certain tax withholding obligations in connection with the issuance of shares upon the vesting of certain shares of common stock subject to certain performance restricted stock unit awards. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $56.46 to $57.45, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| July 29, 2024 Filed Jul 31, 2024 20:05 UTC | Viking Therapeutics, Inc. VKTX · Entity 4067 | GrantCommon Stock, par value $0.00001 per share | 163,333 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-088544 · ownership.xml · nonDerivative · entry 2 Lian Brian · CIK 0001614578 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,470,786 F2 · shares: The reported securities were subject to a performance restricted stock unit award that was granted on January 3, 2024, 33.33% of which vested on July 29, 2024 upon the achievement of a non-financial performance goal. Read SEC document |
| July 29, 2024 Filed Jul 31, 2024 20:05 UTC | Viking Therapeutics, Inc. VKTX · Entity 4067 | GrantCommon Stock, par value $0.00001 per share | 41,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-088544 · ownership.xml · nonDerivative · entry 1 Lian Brian · CIK 0001614578 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,307,453 F1 · shares: The reported securities were subject to a performance restricted stock unit award that was granted on January 4, 2021, 33.33% of which vested on July 29, 2024 upon the achievement of a non-financial performance goal. Read SEC document |
| March 27, 2024 Filed Mar 28, 2024 00:51 UTC | Viking Therapeutics, Inc. VKTX · Entity 4067 | Tax withholdingCommon Stock, par value $0.00001 per share | 153,948 | $83.34 | $12,830,026.32 |
DisclosureSEC source: 0001209191-24-005117 · doc4.xml · nonDerivative · entry 2 Lian Brian · CIK 0001614578 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,266,453 F2 · shares: These shares were withheld by the Issuer in order to satisfy certain tax withholding obligations in connection with the issuance of shares upon the vesting of certain shares of common stock subject to certain performance restricted stock units. Read SEC document |
| March 27, 2024 Filed Mar 28, 2024 00:51 UTC | Viking Therapeutics, Inc. VKTX · Entity 4067 | GrantCommon Stock, par value $0.00001 per share | 221,667 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-24-005117 · doc4.xml · nonDerivative · entry 1 Lian Brian · CIK 0001614578 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,420,401 F1 · shares: The reported securities were subject to a performance restricted stock unit award that was granted on January 3, 2023, 33.33% of which vested on March 27, 2024 upon the achievement of a non-financial performance goal. Read SEC document |
| March 01, 2024 Filed Mar 5, 2024 00:54 UTC | Viking Therapeutics, Inc. VKTX · Entity 4067 | Tax withholdingCommon Stock, par value $0.00001 per share | 162,815 | $85.22 | $13,875,094.30 |
DisclosureSEC source: 0001209191-24-004233 · doc4.xml · nonDerivative · entry 2 Lian Brian · CIK 0001614578 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,198,734 F2 · shares: These shares were withheld by the Issuer in order to satisfy certain tax withholding obligations in connection with the issuance of shares upon the vesting of certain shares of common stock subject to certain performance restricted stock units. Read SEC document |
| March 01, 2024 Filed Mar 5, 2024 00:54 UTC | Viking Therapeutics, Inc. VKTX · Entity 4067 | GrantCommon Stock, par value $0.00001 per share | 221,667 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-24-004233 · doc4.xml · nonDerivative · entry 1 Lian Brian · CIK 0001614578 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,361,549 F1 · shares: The reported securities were subject to a performance restricted stock unit award that was granted on January 3, 2023, 33.33% of which vested on March 1, 2024 upon the achievement of a non-financial performance goal. Read SEC document |
| February 09, 2024 Filed Feb 10, 2024 01:59 UTC | Viking Therapeutics, Inc. VKTX · Entity 4067 | SaleCommon Stock, par value $0.00001 per share | 45,000 | $29.90 | $1,345,500.00 |
DisclosureSEC source: 0001209191-24-003068 · doc4.xml · nonDerivative · entry 1 Lian Brian · CIK 0001614578 · Director · President & CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 2,139,882 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule10b5-1 trading plan adopted by the Reporting Person on September 29, 2023. Read SEC document |
| February 08, 2024 Filed Feb 9, 2024 00:40 UTC | Viking Therapeutics, Inc. VKTX · Entity 4067 | Exercise / conversionStock Option (right to buy) · Derivative | 140,000 | $0.00 Strike: $4.65 | $0.00 |
DisclosureSEC source: 0001209191-24-003010 · doc4.xml · derivative · entry 10 Lian Brian · CIK 0001614578 · Director · President & CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 140,000 shares Expires 2028-01-19 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule10b5-1 trading plan adopted by the Reporting Person on September 29, 2023. F2 · derivative.exercise_date: 25% of the shares subject to the option vested on each one year anniversary of the grant date. Read SEC document |
| February 08, 2024 Filed Feb 9, 2024 00:40 UTC | Viking Therapeutics, Inc. VKTX · Entity 4067 | Exercise / conversionStock Option (right to buy) · Derivative | 34,931 | $0.00 Strike: $1.23 | $0.00 |
DisclosureSEC source: 0001209191-24-003010 · doc4.xml · derivative · entry 9 Lian Brian · CIK 0001614578 · Director · President & CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 34,931 shares Expires 2027-01-05 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule10b5-1 trading plan adopted by the Reporting Person on September 29, 2023. Read SEC document |
| February 08, 2024 Filed Feb 9, 2024 00:40 UTC | Viking Therapeutics, Inc. VKTX · Entity 4067 | Exercise / conversionStock Option (right to buy) · Derivative | 14,148 | $0.00 Strike: $1.23 | $0.00 |
DisclosureSEC source: 0001209191-24-003010 · doc4.xml · derivative · entry 8 Lian Brian · CIK 0001614578 · Director · President & CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 14,148 shares Expires 2027-01-05 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule10b5-1 trading plan adopted by the Reporting Person on September 29, 2023. F2 · derivative.exercise_date: 25% of the shares subject to the option vested on each one year anniversary of the grant date. Read SEC document |
| February 08, 2024 Filed Feb 9, 2024 00:40 UTC | Viking Therapeutics, Inc. VKTX · Entity 4067 | SaleCommon Stock, par value $0.00001 per share | 40,000 | $28.90 | $1,156,000.00 |
DisclosureSEC source: 0001209191-24-003010 · doc4.xml · nonDerivative · entry 7 Lian Brian · CIK 0001614578 · Director · President & CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 2,184,882 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule10b5-1 trading plan adopted by the Reporting Person on September 29, 2023. Read SEC document |
| February 08, 2024 Filed Feb 9, 2024 00:40 UTC | Viking Therapeutics, Inc. VKTX · Entity 4067 | SaleCommon Stock, par value $0.00001 per share | 40,000 | $27.45 | $1,098,000.00 |
DisclosureSEC source: 0001209191-24-003010 · doc4.xml · nonDerivative · entry 6 Lian Brian · CIK 0001614578 · Director · President & CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 2,224,882 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule10b5-1 trading plan adopted by the Reporting Person on September 29, 2023. Read SEC document |
| February 08, 2024 Filed Feb 9, 2024 00:40 UTC | Viking Therapeutics, Inc. VKTX · Entity 4067 | SaleCommon Stock, par value $0.00001 per share | 80,000 | $26.95 | $2,156,000.00 |
DisclosureSEC source: 0001209191-24-003010 · doc4.xml · nonDerivative · entry 5 Lian Brian · CIK 0001614578 · Director · President & CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 2,264,882 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule10b5-1 trading plan adopted by the Reporting Person on September 29, 2023. Read SEC document |
| February 08, 2024 Filed Feb 9, 2024 00:40 UTC | Viking Therapeutics, Inc. VKTX · Entity 4067 | SaleCommon Stock, par value $0.00001 per share | 60,000 | $25.95 | $1,557,000.00 |
DisclosureSEC source: 0001209191-24-003010 · doc4.xml · nonDerivative · entry 4 Lian Brian · CIK 0001614578 · Director · President & CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 2,344,882 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule10b5-1 trading plan adopted by the Reporting Person on September 29, 2023. Read SEC document |
| February 08, 2024 Filed Feb 9, 2024 00:40 UTC | Viking Therapeutics, Inc. VKTX · Entity 4067 | Exercise / conversionCommon Stock, par value $0.00001 per share | 140,000 | $4.65 | $651,000.00 |
DisclosureSEC source: 0001209191-24-003010 · doc4.xml · nonDerivative · entry 3 Lian Brian · CIK 0001614578 · Director · President & CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 2,404,882 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule10b5-1 trading plan adopted by the Reporting Person on September 29, 2023. Read SEC document |
| February 08, 2024 Filed Feb 9, 2024 00:40 UTC | Viking Therapeutics, Inc. VKTX · Entity 4067 | SaleCommon Stock, par value $0.00001 per share | 49,079 | $25.75 | $1,263,784.25 |
DisclosureSEC source: 0001209191-24-003010 · doc4.xml · nonDerivative · entry 2 Lian Brian · CIK 0001614578 · Director · President & CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 2,264,882 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule10b5-1 trading plan adopted by the Reporting Person on September 29, 2023. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.